Prevalence and Economic Burden of Respiratory Diseases in Central Asia and Russia: A Systematic Review

Abstract

Prevalence data of respiratory diseases (RDs) in Central Asia (CA) and Russia are contrasting. To inform future research needs and assist government and clinical policy on RDs, an up-to-date overview is required. We aimed to review the prevalence and economic burden of RDs in CA and Russia. PubMed and EMBASE databases were searched for studies that reported prevalence and/or economic burden of RDs (asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, interstitial lung diseases (ILD), lung cancer, pulmonary hypertension, and tuberculosis (TB)) in CA (Kyrgyzstan, Uzbekistan, Tajikistan, Kazakhstan, and Turkmenistan) and Russia. A total of 25 articles (RD prevalence: 18; economics: 7) were included. The majority (n = 12), mostly from Russia, reported on TB. TB prevalence declined over the last 20 years, to less than 100 per 100,000 across Russia and CA, yet in those, multidrug-resistant tuberculosis (MDR-TB) was alarming high (newly treated: 19–26%, previously treated: 60–70%). COPD, asthma (2–15%) and ILD (0.006%) prevalence was only reported for Russia and Kazakhstan. No studies on cystic fibrosis, lung cancer and pulmonary hypertension were found. TB costs varied between US$400 (Tajikistan) and US$900 (Russia) for drug-susceptible TB to ≥US$10,000 for MDR-TB (Russia). Non-TB data were scarce and inconsistent. Especially in CA, more research into the prevalence and burden of RDs is needed.

Plant-Derived Natural Products as Lead Agents against Common Respiratory Diseases

“…The annual cost of treatment for patients with an RD in the Asia-Pacific region was estimated at USD 4191 per patient, while the mean annual cost of treatment for patients who reported lung impairment at work was USD 7315 in 2014, thus resulting in a 36% reduction in productivity [ 60 ]. In the Central Asian countries (Eurasia) such as Kyrgyzstan, Uzbekistan, Tajikistan, Kazakhstan and Turkmenistan, the prevalence of TB is still significantly high, placing enormous costs on the government and patients [ 61 ]. In sub-Saharan Africa, deaths associated with solid fuel rose by 18% between 1990 and 2013 and cost the African economy approximately USD 232 billion by the year 2013 [ 62 ].…”

Impact of ambient temperature on respiratory disease: a case-crossover study in Seoul

“…In 2019, chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma, and other respiratory conditions, were the third leading cause of death globally, resulting in 4.0 million deaths and affecting 454.6 million individuals [1,2]. These diseases also impose a substantial burden on healthcare systems owing to hospitalisations, emergency department visits, and long-term care expenses [3][4][5][6]. Furthermore, respiratory infections, including upper and lower respiratory tract infections, contribute to a substantial global burden, with billions of cases and millions of deaths reported annually [7,8].…”

Lived Experiences of Adolescents with Asthma: Struggle to Maintain Daily Life

“…The burden of asthma is particularly high in adolescence, with an increased prevalence and mortality compared with younger children [5,6]. For example, worldwide asthma affects 300 million people, and this is expected to increase to more than 100 million by 2025.…”